Mesenchymal stem cells exhibit resistance to topoisomerase inhibition

Cancer Letters

Volumn 374, Issue 1, 2016, Pages 75-84

  Nicolay, Nils H ^a,b,c   Rühle, Alexander ^b,c   Perez, Ramon Lopez ^c   Trinh, Thuy ^a,b   Sisombath, Sonevisay ^c   Weber, Klaus Josef ^a,b   Schmezer, Peter ^c   Ho, Anthony D ^a   Debus, Jürgen ^a,b   Saffrich, Rainer ^a   Huber, Peter E ^a,b,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Heidelberg Institute for Radiation Oncology (HIRO)   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Bone marrow toxicity; Chemotherapy; Etoposide; Irinotecan; Mesenchymal stem cells; Topoisomerase inhibitor

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GYRASE INHIBITOR; IRINOTECAN;

ANALOGS AND DERIVATIVES; APOPTOSIS; CELL ADHESION; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FIBROBLAST; HUMAN; MCF 7 CELL LINE; MESENCHYMAL STROMA CELL; PHYSIOLOGY;

APOPTOSIS; CAMPTOTHECIN; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; DRUG RESISTANCE; ETOPOSIDE; FIBROBLASTS; HUMANS; MCF-7 CELLS; MESENCHYMAL STROMAL CELLS; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS;

EID: 84959387547     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.007     Document Type: Article

References (61)

1. Friedenstein A.J., Deriglasova U.F., Kulagina N.N., Panasuk A.F., Rudakowa S.F., Luria E.A., et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp. Hematol 1974, 2(2):83-92.
2. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
3. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8(4):315-317.
4. Sugrue T., Lowndes N.F., Ceredig R. Mesenchymal stromal cells: radio-resistant members of the bone marrow. Immunol. Cell Biol 2013, 91(1):5-11.
5. Nicolay N.H., Lopez Perez R., Saffrich R., Huber P.E. Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic. Oncotarget 2015, 6(23):19366-19380.
6. Ehninger A., Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J. Exp. Med 2011, 208(3):421-428.
7. Nicolay N.H., Lopez Perez R., Debus J., Huber P.E. Mesenchymal stem cells - a new hope for radiotherapy-induced tissue damage?. Cancer Lett 2015, 366(2):133-140.
8. Macmillan M.L., Blazar B.R., DeFor T.E., Wagner J.E. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009, 43(6):447-454.
9. Le Blanc K., Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant 2005, 11(5):321-334.
10. Pommier Y., Leo E., Zhang H., Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol 2010, 17(5):421-433.
11. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem 2001, 70:369-413.
12. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400(1-3):83-105.
13. Roca J. Topoisomerase II: a fitted mechanism for the chromatin landscape. Nucleic Acids Res 2009, 37(3):721-730.
14. Pizzolato J.F., Saltz L.B. The camptothecins. Lancet 2003, 361(9376):2235-2242.
15. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.I., Sim G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J. Am. Chem. Soc 1966, 88:3888-3890.
16. Colucci G., Gebbia V., Paoletti G., Giuliani F., Caruso M., Gebbia N., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol 2005, 23(22):4866-4875.
17. Eckardt J.R., von Pawel J., Papai Z., Tomova A., Tzekova V., Crofts T.E., et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J. Clin. Oncol 2006, 24(13):2044-2051.
18. Sehouli J., Stengel D., Oskay-Oezcelik G., Zeimet A.G., Sommer H., Klare P., et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol 2008, 26(19):3176-3182.
19. Maksymiuk A.W., Jett J.R., Earle J.D., Su J.Q., Diegert F.A., Mailliard J.A., et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J. Clin. Oncol 1994, 12(1):70-76.
20. Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J. Clin. Oncol 2008, 26(18):2966-2972.
21. Goorin A.M., Harris M.B., Bernstein M., Ferguson W., Devidas M., Siegal G.P., et al. III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J. Clin. Oncol 2002, 20(2):426-433.
22. Hartmann J.T., Lipp H.P. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug saf 2006, 29(3):209-230.
23. Wagner W., Wein F., Seckinger A., Frankhauser M., Wirkner U., Krause U., et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp. Hematol 2005, 33(11):1402-1416.
24. Nicolay N.H., Liang Y., Lopez Perez R., Bostel T., Trinh T., Sisombath S., et al. Mesenchymal stem cells are resistant to carbon ion radiotherapy. Oncotarget 2015, 6(4):2076-2087.
25. Davies S.M., Harris A.L., Hickson I.D. Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant. Nucleic Acids Res 1989, 17(4):1337-1351.
26. Chabot G.G. Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet 1997, 33(4):245-259.
27. Hande K.R. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells 1996, 14(1):18-24.
28. Liang W., Xia H., Li J., Zhao R.C. Human adipose tissue derived mesenchymal stem cells are resistant to several chemotherapeutic agents. Cytotechnology 2011, 63(5):523-530.
29. Nicolay N.H., Sommer E., Lopez R., Wirkner U., Trinh T., Sisombath S., et al. Mesenchymal stem cells retain their defining stem cell characteristics after exposure to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys 2013, 87(5):1171-1178.
30. Nicolay N.H., Sommer E., Perez R.L., Wirkner U., Bostel T., Ho A.D., et al. Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation. Strahlenther. Onkol 2014, 190(11):1037-1045.
31. Rylova J.V., Andreeva E.R., Gogvadze V.G., Zhivotovsky B.D., Buravkova L.B. Etoposide and hypoxia do not activate apoptosis of multipotent mesenchymal stromal cells in vitro. Bull. Exp. Biol. Med 2012, 154(1):141-144.
32. Nicolay N.H., Lopez Perez R., Rühle A., Trinh T., Sisombath S., Weber K.J., et al. Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin. Sci. Rep 2016, 6:20035. in press.
33. Lu C., Lu S., Liang W., Li J., Dou X., Bian C., et al. TAp63alpha mediates chemotherapeutic agent-induced apoptosis in human bone marrow mesenchymal stem cells. Stem Cells Dev 2011, 20(8):1319-1326.
34. Liang W., Lu C., Li J., Yin J.Q., Zhao R.C. p73alpha regulates the sensitivity of bone marrow mesenchymal stem cells to DNA damage agents. Toxicology 2010, 270(1):49-56.
35. Mueller L.P., Luetzkendorf J., Mueller T., Reichelt K., Simon H., Schmoll H.J. Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells 2006, 24(12):2753-2765.
36. Jin Y.W., Na Y.J., Lee Y.J., An S., Lee J.E., Jung M., et al. Comprehensive analysis of time- and dose-dependent patterns of gene expression in a human mesenchymal stem cell line exposed to low-dose ionizing radiation. Oncol. Rep 2008, 19(1):135-144.
37. Adams S.W., Wang L., Fortney J., Gibson L.F. Etoposide differentially affects bone marrow and dermal derived endothelial cells. J. Cell. Mol. Med 2004, 8(3):338-348.
38. Marengo B., De Ciucis C.G., Ricciarelli R., Furfaro A.L., Colla R., Canepa E., et al. p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment. Cell Death Dis 2013, 4:e589.
39. Lin S.S., Sun L., Zhang Y.K., Zhao R.P., Liang W.L., Yuan S.T., et al. Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases. Acta Pharmacol. Sin 2009, 30(5):628-636.
40. Allen W.L., Turkington R.C., Stevenson L., Carson G., Coyle V.M., Hector S., et al. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. Mol. Cancer Ther 2012, 11(8):1724-1734.
41. Kim J.H., Jeong M., Lee S.S., Song J. Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARgamma. Biochem. Biophys. Res. Commun 2015, 463(4):1122-1128.
42. Yamagishi T., Otsuka E., Hagiwara H. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinology 2001, 142(8):3632-3637.
43. Wijdeven R.H., Pang B., van der Zanden S.Y., Qiao X., Blomen V., Hoogstraat M., et al. Genome-wide identification and characterization of novel factors conferring resistance to topoisomerase II poisons in cancer. Cancer Res 2015, 75(19):4176-4187.
44. Alagoz M., Gilbert D.C., El-Khamisy S., Chalmers A.J. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr. Med. Chem 2012, 19(23):3874-3885.
45. Smith P.J., Anderson C.O., Watson J.V. Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts. Cancer Res 1986, 46(11):5641-5645.
46. Zhao H., Traganos F., Darzynkiewicz Z. Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. Cytometry A. 2008, 73(6):480-489.
47. Quennet V., Beucher A., Barton O., Takeda S., Lobrich M. CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1. Nucleic Acids Res 2011, 39(6):2144-2152.
48. Lundin C., Schultz N., Arnaudeau C., Mohindra A., Hansen L.T., Helleday T. RAD51 is involved in repair of damage associated with DNA replication in mammalian cells. J. Mol. Biol 2003, 328(3):521-535.
49. Prendergast A.M., Cruet-Hennequart S., Shaw G., Barry F.P., Carty M.P. Activation of DNA damage response pathways in human mesenchymal stem cells exposed to cisplatin or gamma-irradiation. Cell Cycle 2011, 10(21):3768-3777.
50. Radhakrishnan S.K., Jette N., Lees-Miller S.P. Non-homologous end joining: emerging themes and unanswered questions. DNA Repair (Amst) 2014, 17:2-8.
51. Daley J.M., Sung P. 53BP1, BRCA1, and the choice between recombination and end joining at DNA double-strand breaks. Mol. Cell. Biol 2014, 34(8):1380-1388.
52. Cmielova J., Havelek R., Soukup T., Jiroutova A., Visek B., Suchanek J., et al. Gamma radiation induces senescence in human adult mesenchymal stem cells from bone marrow and periodontal ligaments. Int. J. Radiat. Biol 2012, 88(5):393-404.
53. Carrancio S., Blanco B., Romo C., Muntion S., Lopez-Holgado N., Blanco J.F., et al. Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment. PLoS ONE 2011, 6(10). e26241.
54. Battiwalla M., Barrett A.J. Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation. Tissue Eng. Part B Rev 2014, 20(3):211-217.
55. Kim D.S., Lee M.W., Noh Y.H., Jang M.C., Lee S.H., Son M.H., et al. Engraftment efficacy of human hematopoietic stem cells transplanted into NOD/SCID mice using two methods: intra-bone marrow transplantation of hematopoietic stem cells and intravenous co-transplantation with mesenchymal stem cells. Acta Haematol 2014, 131(3):179-182.
56. Wu Y., Wang Z., Cao Y., Xu L., Li X., Liu P., et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy. Ann. Hematol 2013, 92(12):1675-1684.
57. Koc O.N., Peters C., Aubourg P., Raghavan S., Dyhouse S., DeGasperi R., et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp. Hematol 1999, 27(11):1675-1681.
58. Bartsch K., Al-Ali H., Reinhardt A., Franke C., Hudecek M., Kamprad M., et al. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used. Transplantation 2009, 87(2):217-221.
59. Ljujic B., Milovanovic M., Volarevic V., Murray B., Bugarski D., Przyborski S., et al. Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. Sci. Rep 2013, 3:2298.
60. De Boeck A., Pauwels P., Hensen K., Rummens J.L., Westbroek W., Hendrix A., et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut 2013, 62(4):550-560.
61. Bianchi G., Morandi F., Cilli M., Daga A., Bocelli-Tyndall C., Gambini C., et al. Close interactions between mesenchymal stem cells and neuroblastoma cell lines lead to tumor growth inhibition. PLoS ONE 2012, 7(10). e48654.